Treatment of membranous lupus nephritis: Where are we now?

Journal of the American Society of Nephrology

Volumn 20, Issue 4, 2009, Pages 690-691

  Beck, Laurence H ^a   Salant, David J ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ANTIGEN ANTIBODY COMPLEX; BLADDER CANCER; CANCER RISK; DRUG MEGADOSE; EDITORIAL; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; NEPHROTIC SYNDROME; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION;

EID: 65249109263     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009020216     Document Type: Editorial

References (12)

1. Cameron JS: Systemic lupus erythematosus. In: Immunologic Renal Diseases, 2nd Ed., edited by Neilson EG, Couser WG, Philadelphia, Lippincott-Raven, 2001, pp 1057-1104
2. Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 19: 473-479, 1992
3. Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T: Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med 41: 936-942, 2002
4. Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P, Rekvig OP: Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 71: 664-672, 2007
5. Mercadal L, Montcel ST, Nochy D, Queffeulou G, Piette JC, Isnard- Bagnis C, Martinez F: Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 17: 1771-1778, 2002
6. Sloan RP, Schwartz MM, Korbet SM, Borok RZ: Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 7: 299-305, 1996
7. Kolasinski SL, Chung JB, Albert DA: What do we know about lupus membranous nephropathy? An analytic review. Arthritis Rheum 47: 450-455, 2002
8. Austin HA 3rd, Illei GG, Braun MJ, Balow JE: Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20: 901-911, 2009
9. Waldman M, Appel GB: Update on the treatment of lupus nephritis. Kidney Int 70: 1403-1412, 2006
10. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delf-gaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008
11. Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE, Hebert LA: Mycophenolate therapyofSLE membranous nephropathy. Kidney Int 66: 2411-2415, 2004
12. Jacobson SH, van Vollenhoven R, Gunnarsson I: Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 21: 1742-1743, 2006